Drugs / NY-ESO-1 protein
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00821652 | Feb 2009 → Jan 2010 | neoplasm | Nina Bhardwaj | Completed | No outcome recorded |
| Phase 1 | NCT00819806 | Jan 2009 → May 2012 | melanoma tumor antigen Gp90 | Hassane M. Zarour, MD | Completed | No outcome recorded |
| Phase 1 | NCT00292045 | Oct 2004 → Jan 2006 | prostate cancer | Ludwig Institute for Cancer Research | Completed | No outcome recorded |
| Phase 1 | NCT00070070 | Oct 2003 → Jan 2006 | transitional cell carcinoma | Ludwig Institute for Cancer Research | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NY-ESO-1 protein | “PF-3512676, Montanide ISA 720 VG and the NY-ESO-1 protein in three subcutaneous injection (i.e. 3 mg of PF-3512676 or 300 μl of PF-3512676 at 10mg/ml, 300 μg or 900 μl of...” NCT00819806 ↗ |
| Modality | Vaccine | “Here we evaluated the safety and immunogenicity of a recombinant NY-ESO-1 protein vaccine, which was administered with granulocyte macrophage colony-stimulating factor and BCG...” PMID 18833002 ↗ Nov 2008 |
| Route | Subcutaneous | “PF-3512676, Montanide ISA 720 VG and the NY-ESO-1 protein in three subcutaneous injection” NCT00819806 ↗ |